Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
Pichler H, Möricke A, Mann G, Teigler-Schlegel A, Niggli F, Nebral K, König M, Inthal A, Krehan D, Dworzak MN, Janousek D, Harbott J, Schrappe M, Gadner H, Strehl S, Haas OA, Panzer-Grümayer R, Attarbaschi A; Berlin-Frankfurt-Münster (BFM) Study Group. Pichler H, et al. Among authors: harbott j. Br J Haematol. 2010 Apr;149(1):93-100. doi: 10.1111/j.1365-2141.2009.08059.x. Epub 2010 Jan 13. Br J Haematol. 2010. PMID: 20067563 Free article. Clinical Trial.
Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA. Attarbaschi A, et al. Among authors: harbott j. J Clin Oncol. 2008 Jun 20;26(18):3046-50. doi: 10.1200/JCO.2008.16.1117. J Clin Oncol. 2008. PMID: 18565891
Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial.
Attarbaschi A, Panzer-Grümayer R, Mann G, Möricke A, König M, Mecklenbräuker A, Teigler-Schlegel A, Bradtke J, Harbott J, Göhring G, Stanulla M, Schrappe M, Zimmermann M, Haas OA; Austrian and German ALL-BFM (Berlin-Frankfurt-Münster) Study Group. Attarbaschi A, et al. Among authors: harbott j. Klin Padiatr. 2014 Nov;226(6-7):338-43. doi: 10.1055/s-0034-1387795. Epub 2014 Nov 28. Klin Padiatr. 2014. PMID: 25431866 Clinical Trial.
Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection.
Panzer-Grümayer ER, Cazzaniga G, van der Velden VH, del Giudice L, Peham M, Mann G, Eckert C, Schrauder A, Germano G, Harbott J, Basso G, Biondi A, van Dongen JJ, Gadner H, Haas OA. Panzer-Grümayer ER, et al. Among authors: harbott j. Clin Cancer Res. 2005 Nov 1;11(21):7720-7. doi: 10.1158/1078-0432.CCR-05-1239. Clin Cancer Res. 2005. PMID: 16278392
Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfürt-Münster study group.
Harrison CJ, Haas O, Harbott J, Biondi A, Stanulla M, Trka J, Izraeli S; Biology and Diagnosis Committee of International Berlin-Frankfürt-Münster study group. Harrison CJ, et al. Among authors: harbott j. Br J Haematol. 2010 Oct;151(2):132-42. doi: 10.1111/j.1365-2141.2010.08314.x. Br J Haematol. 2010. PMID: 20701601 Free article. Review.
ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling.
Kuster L, Grausenburger R, Fuka G, Kaindl U, Krapf G, Inthal A, Mann G, Kauer M, Rainer J, Kofler R, Hall A, Metzler M, Meyer LH, Meyer C, Harbott J, Marschalek R, Strehl S, Haas OA, Panzer-Grümayer R. Kuster L, et al. Among authors: harbott j. Blood. 2011 Mar 3;117(9):2658-67. doi: 10.1182/blood-2010-03-275347. Epub 2011 Jan 11. Blood. 2011. PMID: 21224468 Free article.
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, Locatelli F, Cazzaniga G, Niggli F, Aricò M, Bartram CR, Attarbaschi A, Silvestri D, Beier R, Basso G, Ratei R, Kulozik AE, Lo Nigro L, Kremens B, Greiner J, Parasole R, Harbott J, Caruso R, von Stackelberg A, Barisone E, Rössig C, Conter V, Schrappe M. Möricke A, et al. Among authors: harbott j. Blood. 2016 Apr 28;127(17):2101-12. doi: 10.1182/blood-2015-09-670729. Epub 2016 Feb 17. Blood. 2016. PMID: 26888258 Free article. Clinical Trial.
Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia.
Wuchter C, Karawajew L, Ruppert V, Schrappe M, Harbott J, Ratei R, Dörken B, Ludwig WD. Wuchter C, et al. Among authors: harbott j. Br J Haematol. 2000 Jul;110(1):154-60. doi: 10.1046/j.1365-2141.2000.02147.x. Br J Haematol. 2000. PMID: 10930993 Free article.
182 results